- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00005409
Longitudinal Studies of Blood Pressure in the Elderly
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
BACKGROUND:
In middle-age, level of blood pressure (BP) is a strong and independent predictor of both total and cardiovascular disease (CVD) mortality. However, among the elderly, recent short-term observational studies, including the East Boston Established Populations for Epidemiologic Studies in the Elderly (EPESE), have raised the possibility of a J-shaped curve. In a study of short-term mortality, low blood pressures were positively associated with total and cardiovascular disease mortality. However, a further analysis confined to the 2079 (68 percent) of this cohort who were also screened nine years previously for the Hypertension Detection and Follow-Up Program showed the more conventional positive linear relationship between systolic blood pressure, and no association between diastolic blood pressure and mortality. The observations of higher short-term total and cardiovascular disease mortality at lower blood pressure levels among the elderly could have reflected a particular susceptibility to deleterious consequences of drug therapy for high blood pressure. Alternatively, such a finding might have been artifactual, due to survival bias or confounding by co-morbid conditions.
DESIGN NARRATIVE:
Linking data from the HDFP and the EPESE studies, the investigators examined change in blood pressure, antihypertensive medication use, and mortality over a 15-year period. With regard to the association between lower blood pressure and increased mortality, they determined whether the relationship previously observed reflected a fall from normotensive levels as opposed to a consistently low blood pressure. With regard to the upper end of the mortality curve, they assessed the effect of antihypertensive drug treatment on mortality as compared to those with untreated hypertension. The latter question had particular public health significance because questions remained about the risk-to-benefit ratio of antihypertensive drug treatment in this age group. Furthermore, they also described changes in blood pressure in this population and medication usage patterns over time and correlated type of medication and mortality.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Undersøgelsestype
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 4327
- R03HL046923 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hjertesygdomme
-
Region SkaneTilmelding efter invitationHjertesvigt New York Heart Association (NYHA) klasse II | Hjertesvigt New York Heart Association (NYHA) klasse IIISverige
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... og andre samarbejdspartnereIkke rekrutterer endnuHjertesvigt, systolisk | Hjertesvigt med reduceret udstødningsfraktion | Hjertesvigt New York Heart Association Klasse IV | Hjertesvigt New York Heart Association Klasse IIIPolen
-
University of WashingtonAmerican Heart AssociationAfsluttetHjertesvigt, Kongestiv | Mitokondriel ændring | Hjertesvigt New York Heart Association Klasse IVForenede Stater
-
Novartis PharmaceuticalsAfsluttetPatienter, der med succes afslutter den 12-måneders behandlingsperiode i kernestudiet (de Novo Heart-modtagere), som var interesserede i at blive behandlet med EC-MPS
-
University Hospital, GasthuisbergUkendtTransient Left Ventricular Ballooning SyndromeBelgien
-
NYU Langone HealthRekrutteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeForenede Stater
-
French Cardiology SocietyAfsluttet